Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Unlabelled: Enterococcal endocarditis (EIE) affects elderly patients, with high rates of complications and mortality, and dalbavancin (DBV) exhibits significant antimicrobial activity against most enterococci. However, data are lacking on the use of DBV in EIE. The main objective was to evaluate the outcomes of treatment with DBV in the consolidation therapy of IE by Enterococcus spp.
Methods: Spanish-French retrospective observational study of patients with EIE enrolled between November 2016 and June 30, 2022 receiving DBV in consolidation phase and followed for ≥12 months.
Results: Ninety-eight patients were enrolled, 69.4 % male, with mean age of 71.2 (±12.51) years and median Charlson index of 5 (IQR 3-7). Criteria for definite IE were met by 84.7%; 60.2 % had IE on native valve, 26.5 % late prosthetic IE, 8.2 % early prosthetic IE, 2 % cardiovascular implantable electronic-IE (CIE-IE), and 3.1 % CIE-IE and valve. Aortic valve involvement was observed in 66.3 %. E. faecalis was isolated in 86.7 %, E. faecium in 11.2 %; 32.6 % underwent surgery, and these had a higher cure rate (100 % vs 75.8 %; p = 0.005) and lower mortality (0 vs 13.6 %; p = 0.029). DBV was administered to facilitate discharge in 88.8 %. Total dose was 2500 mg (1500-3000) over 3.5 weeks (2-4). Loss to follow-up was 0 %, relapse rate 8.2 %, 1-year IE-related mortality 3.1 %, and clinical cure rate 81.2 %. Severe adverse events affected 1 % (acute tubular necrosis). Hospital stay was reduced by 21 days (14-28).
Conclusions: DBV appears to be highly effective, safe, and cost-effective as consolidation therapy in patients with IE caused by Enterococcus spp., with minimal adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jmii.2025.03.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
It's "Blin" a Long Time Coming: The Rise of Blinatumomab in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
Clin Lymphoma Myeloma Leuk
August 2025
Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI. Electronic address:
Blinatumomab is a bispecific T-cell engager that has recently transformed front-line treatment for many patients with Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL). It was originally studied in relapsed/refractory disease, then moved to targeting measurable residual disease (MRD), and has since been shown to improve outcomes for almost every age group when added to consolidation chemotherapy. The evidence supporting blinatumomab is most robust in adult and standard-risk pediatric age groups, but its benefit in adolescents and young adults and high-risk pediatric patients is not yet understood.
View Article and Find Full Text PDFLiver Transplant for Intrahepatic Cholangiocarcinoma: Current Evidence and Clinical Practice Recommendations.
J Gastrointest Surg
September 2025
Department of Surgery, Massachusetts General Hospital, Boston, MA. Electronic address:
Intrahepatic cholangiocarcinoma (iCCA) incidence is increasing globally and is associated with poor prognosis. Surgical resection remains the main curative treatment. However, many patients present with unresectable disease or underlying liver dysfunction, precluding resection.
View Article and Find Full Text PDFConsensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in China.
ESMO Open
September 2025
Institute of Oncology, Guangxi Academy of Medical Sciences, Nanning, Guangxi, China; Department of Otolaryngology & Head and Neck, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China. Electronic address:
Introduction: This study aims to establish a multidisciplinary consensus on the treatment of nasopharyngeal carcinoma (NPC) in China, with a particular focus on the guidelines for the use of immune checkpoint inhibitors (ICIs) to ensure scientific and rational treatment protocols.
Methods: The consensus was formulated based on the 'guidelines for the diagnosis and treatment of NPC (2024 edition)' issued by the Chinese Society of Clinical Oncology. The Delphi method was used to collect and consolidate expert opinions.
Purpose Of Review: Autologous stem cell transplantation (ASCT) has long been a cornerstone in the treatment of eligible patients with newly diagnosed multiple myeloma (NDMM). In this review, we analyze the evolving role of ASCT in the contemporary period.
Recent Findings: With the growing integration of modern induction regimens and advanced immunotherapies such as chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies (BsAbs), the traditional paradigm of multiple myeloma treatment is being increasingly challenged.
A Case of Complete Remission Achieved Through Stereotactic Radiotherapy for Isolated Bone Metastasis Following Four Courses of Bleomycin, Etoposide, and Cisplatin Chemotherapy for Testicular Cancer.
IJU Case Rep
September 2025
Department of Urology Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital Niigata Japan.
Introduction: We report a case of nonseminoma germ cell tumor, in which solitary bone metastasis was detected by magnetic resonance imaging (MRI) after systemic chemotherapy, and resolution was achieved with stereotactic radiotherapy.
Case Presentation: A 42-year-old man was diagnosed with right-sided testicular cancer, T1N1M0, and right high orchiectomy was performed. Pathology revealed a mixed germ cell tumor.